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Glucocorticoids are potent antiinflammatory drugs. They inhibit the expression of proinflammatory cytokines and adhesion
molecules. It has recently been proposed that the underlying basis to such inhibition is the induction of the protein IkB, which
inhibits the transcription factor NF-kB. The latter is a key activator of the genes encoding cytokines and adhesion molecules. The
present study shows that the synthetic glucocorticoid, dexamethasone, inhibits the induction of the proinflammatory cytokine IL-8
and the adhesion molecules VCAM-1 and ICAM-1 in human 1321N1 astrocytoma and SK.N.SH neuroblastoma cells. However,
dexamethasone failed to induce IkB or inhibit activation of NF-kB by IL-1 in the two cell types. EMSA confirmed the identity of
the activated NF-kB by demonstrating that an oligonucleotide, containing the wild-type NF-kB-binding motif, inhibited formation
of the NF-kB-DNA complexes whereas a mutated form of the NF-kB-binding motif was ineffective. In addition, supershift analysis
showed that the protein subunits p50 and p65 were prevalent components in the activated NF-kB complexes. The lack of effect
of dexamethasone on the capacity of IL-1 to activate NF-kB correlated with its inability to induce IkB and the ability of IL-1 to
cause degradation of IkB, even in the presence of dexamethasone. The results presented in this paper strongly suggest that
glucocorticoids may exert antiinflammatory effects in cells of neural origin by a mechanism(s) independent of NF-kB. The
Journal of Immunology, 1999, 163: 2113–2119.
G lucocorticoids are widely used immunosuppressive andantiinflammatory agents (1). They exert such effects byinhibiting the expression of genes encoding various ad-
hesion molecules and cytokines (2–6). Much work has recently
probed the molecular mechanism by which glucocorticoids may
modulate the expression of these genes and has concentrated on
the NF-kB-Rel transcription factor family as a prime target (7).
The most common form of active NF-kB is a heterodimer con-
sisting of two DNA binding subunits of 50 kDa (p50) and 65 kDa
(p65) that together recognize and contact a specific decameric
DNA sequence (8). Most cells contain latent NF-kB in the cyto-
plasm, where it is rendered inactive via its association with an
inhibitory protein IkB (9). The latter not only prevents nuclear
uptake of NF-kB by masking nuclear location signals (10) but also
inhibits the binding of NF-kB to its DNA recognition sequence (9).
Several different types of IkB3 have been described including
IkBa, IkBb, and IkBe (11, 12). Activation of cells by proinflam-
matory cytokines such as IL-1 effects the dissociation of IkB from
NF-kB via serine phosphorylation and subsequent proteasomal
proteolysis of the IkB inhibitory subunit, thus releasing an active
NF-kB heterodimer that is translocated into the nucleus (13, 14).
This facilitates induction of NF-kB-regulated genes such as those
encoding adhesion molecules and cytokines (15). Recent reports
have suggested that glucocorticoids exert their immunosuppressive
effects by inhibiting the action of NF-kB (16, 17). The studies
report that glucocorticoids induce the transcription of the IkBa
gene, causing increased IkBa protein synthesis, which serves to
sequester active NF-kB in inactive cytoplasmic complexes. The
reduction in levels of active NF-kB would presumably culminate
in decreased expression of adhesion molecules and cytokines.
One of the authors has previously reported that IL-1 can cause
proinflammatory effects in glial cells such as the induction of the
NF-kB-regulated adhesion molecules VCAM-1 and ICAM-1 (18).
We predicted that glucocorticoids would act to modulate the in-
duction of these molecules by virtue of their reported inhibitory
effects on NF-kB. Indeed, the present study demonstrates that the
synthetic glucocorticoid, dexamethasone, inhibits the induction of
these adhesion molecules and IL-8, another protein whose expres-
sion is regulated by NF-kB. However, we also found that gluco-
corticoids can reduce the expression of these proteins in cir-




The human 1321N1 astrocytoma and SK.N.SH neuroblastoma were ob-
tained from European Collection of Animal Cell Cultures (Salisbury,
U.K.). RPMI, penicillin, streptomycin, and FCS were obtained from Life
Technologies (Grand Island, NY). IL-1b was obtained from the National
Cancer Institute (Frederick, MD). Dexamethasone was obtained from
Sigma (Poole, U.K.). The matched Ab pairs against IL-8 were obtained
from R&D Systems (Abingdon, U.K.). The 21-bp oligonucleotides con-
taining the wild-type NF-kB binding motif from the human IL-8 promoter
(underlined) (59-ATCGTGGAATTTCCTCTGACA-39) or the mutated
NF-kB motif (mutated bases in bold) (59-ATCGTTAACTTTCCTCT
GACA-39) were obtained from MWG Biotech (Milton Keynes, U.K.). T4
polynucleotide kinase was obtained from Promega (Madison, WI).
[g-32P]ATP (10 mCi/mmol) and poly(dI-dC) were obtained from Amer-
sham (Bucks, U.K.). The anti-p50, p65, and c-rel antisera were gifts from
Dr. Luke O’Neill (Trinity College, Dublin, Ireland). Anti-IkBa (Mad 3)
(C-15) Abs were obtained from Santa Cruz Biotechnology (Santa Cruz,
CA). HRP-conjugated sheep anti-rabbit IgG and the Boehringer Mannheim
(Mannheim, Germany) chemiluminescence Western blotting kit were ob-
tained from Boehringer Mannheim. The luciferase assay system with re-
porter lysis buffer was obtained from Promega.
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1321N1 and SK.N.SH cells were cultured in DMEM supplemented with
100 U/ml penicillin, 100 mg/ml streptomycin, and 10% (v/v) FCS. The
cells were maintained at 37°C in a humidified atmosphere of 5% CO2 and
passaged using 0.25% (w/v) trypsin in DMEM. IL-1b stimulation was
performed on cells in serum-containing medium at 37°C for all
experiments.
Assay of cell adhesion molecules and IL-8
1321N1 and SK.N.SH cells (5 3 104 cells/0.25 ml) were plated into 96-
well microtiter plates and allowed to adhere for 72 h. Cells were then
stimulated with various concentrations of IL-1b for 24 h. In some exper-
iments, cells were pretreated with various concentrations of dexamethasone
for 15 h before IL-1b (10 ng/ml) treatment for an additional 24 h. Stim-
ulation was terminated by removal of medium, which was subsequently
assayed for IL-8 using matched Ab pairs (R&D Systems) in a sandwich
ELISA system according to the supplier’s instruction. The adherent
cells were measured for expression of VCAM-1 and ICAM-1 as described
previously (18).
Preparation of subcellular fractions
1321N1 and SK.N.SH (2 3 105 cells/ml; 5 ml) were plated into 25-cm2
flasks and allowed to adhere for 72 h. Cells were pretreated for 15 h in the
absence or presence of various concentrations of dexamethasone and then
stimulated with and without IL-1b (10 ng/ml) for 30 min. Stimulation was
terminated by removal of medium and cells were washed with 5 ml ice-
cold PBS. Cells were then scraped into 1 ml ice-cold hypotonic buffer (10
mM HEPES-NaOH buffer, pH 7.9, containing 1.5 mM MgCl2, 10 mM
KCl, 0.5 mM DTT, and 0.5 mM PMSF). Cells were pelleted by centrifu-
gation at 21,000 3 g for 10 min and then lysed for 10 min on ice in
hypotonic buffer (20 ml) containing 0.1% (v/v) Nonidet P-40. Lysates were
centrifuged at 21,000 3 g for 10 min. The resulting supernatants consti-
tuted cytosolic fractions and were measured for levels of IkB by Western
immunoblotting as described below. The pellets were resuspended in 20
mM HEPES-NaOH buffer, pH 7.9 (15 ml), containing 420 mM NaCl, 1.5
mM MgCl2, 0.2 mM EDTA, 25% (w/v) glycerol, and 0.5 mM PMSF and
incubated for 15 min on ice. Incubations were then centrifuged at 21,000 3
g for 10 min and the supernatants removed into 10 mM HEPES/NaOH
buffer, pH 7.9 (75 ml), containing 50 mM KCl, 0.2 mM EDTA, 20% (w/v)
glycerol, 0.5 mM PMSF, and 0.5 mM DTT. Such samples constituted
nuclear extracts and were assayed for NF-kB by EMSA as described
previously (18).
EMSA
Nuclear extracts (4–10 mg protein) were incubated with 20,000 cpm of a
21-bp oligonucleotide, containing the wild-type NF-kB binding motif from
the human IL-8 promoter, which had been previously labeled with
[g-32P]ATP (10 mCi/mmol) by T4 polynucleotide kinase (19). Incubations
were performed for 30 min at room temperature in the presence of 2 mg
poly(dI-dC) and 10 mM Tris-HCl buffer, pH 7.5, containing 100 mM NaCl,
1 mM EDTA, 5 mM DTT, 4% (w/v) glycerol, and 0.1 mg/ml nuclease-free
BSA. In some experiments, unlabeled oligonucleotides, containing the
wild-type or mutated NF-kB motif from the IL-8 promoter (20 pmol each),
or polyclonal antisera (1 ml) against the NF-kB subunits, p50, p65, and
c-rel, were added to the extracts 30 min before incubating with labeled
oligonucleotide. All incubations were subjected to electrophoresis on na-
tive 4% (w/v) polyacrylamide gels, which were subsequently dried and
autoradiographed.
Western immunoblotting
Cytosolic fractions (20 mg protein) were subjected to SDS-PAGE on 12%
polyacrylamide slab gels. The separated proteins were electrophoretically
transferred (80 mA, 1 h) from the gels to nitrocellulose in 0.192 M gly-
cine/25 mM Tris, pH 8.3, containing 1.3 mM SDS and 15% (v/v) methanol,
using a Hoefer TE70 Semiphor semidry transfer unit. The nitrocellulose
was blocked overnight at room temperature in 20 mM Tris buffer, pH 7.5,
containing 0.5 M NaCl and 5% (w/v) powdered milk (Marvel) (Premier
Beverages, Stafford, U.K.), and then washed three times (10 min each) with
20 mM Tris buffer, pH 7.5, containing 0.5 M NaCl and 0.05% (v/v) Tween
20. The washed nitrocellulose was incubated with a 1 mg/ml of anti-IkBa
(Mad 3) (C-15) Abs in 20 mM Tris buffer, pH 7.5 containing 0.5 M NaCl,
0.05% (v/v) Tween 20 and 1% (w/v) Marvel for 2 h at room temperature.
The nitrocellulose was then washed six times (5 min each) as above before
incubation for 1 h at room temperature with a 1:1000 dilution of HRP-
conjugated sheep anti-rabbit IgG in 20 mM Tris buffer, pH 7.5, containing
0.5 M NaCl, 0.05% (v/v) Tween 20, and 1% (w/v) Marvel. After a further
six washes (5 min each) as above, immunoreactive bands were visualized
using the Boehringer Mannheim chemiluminescence Western blotting kit
(Boehringer Mannheim) as recommended by the manufacturers.
Electroporation and assay of luciferase
Trypsinized 1321N1 astrocytoma (1 3 107 cells) were resuspended in PBS
(250 ml) containing a NF-kB reporter plasmid (5 mg of DNA). The latter
consisted of five copies of the NF-kB consensus site cloned into the lu-
ciferase reporter construct pGL3-Basic (Promega). The suspended cells
were electroporated (250 V, 25 mA, maximum capacitance) by means of
an Electroporator II (Invitrogen, San Diego, CA). Aliquots (3 ml) of elec-
troporated cells were seeded into 6-well plates (4 3 105 cells/well) and
incubated for 24 h in DMEM supplemented with 100 U/ml of penicillin,
100 mg/ml of streptomycin, and 10% (v/v) of FCS in a humidified atmo-
sphere of 5% CO2 at 37°C. Cells were subsequently treated in the absence
or presence of various concentrations of dexamethasone for 15 h before
being stimulated in the absence or presence of IL-1b (10 ng/ml) for a
further 24 h. Cells extracts were generated and measured for luciferase
activity using the luciferase assay system with reporter lysis buffer from
Promega.
Results
Dexamethasone inhibits the IL-1b-induction of VCAM-1, ICAM-
1, and IL-8 in 1321N1 astrocytoma
Human 1321N1 astrocytoma were stimulated with various con-
centrations of IL-1b for a 24-h period and measured for VCAM-1,
ICAM-1, and IL-8 by use of ELISA-based detection systems. As
shown previously by one of the authors (18), neither VCAM-1 or
ICAM-1 were expressed at detectable levels in untreated cells, but
IL-1 caused a dose-dependent induction of both adhesion mole-
cules (Fig. 1, A and B). We also demonstrate in the present study
that IL-1 induces expression of the chemokine IL-8 in these cells
(Fig. 1C). Because the induction of these genes in glial cells may
be crucial in mediating leukocytic infiltration of brain leading to
neuropathological states, the search for pharmacological agents
that could modulate the induction was considered valuable. The
presence of NF-kB-binding sites in the promoter regions of the
genes coupled with the previous reports describing the inhibitory
effects of glucocorticoids on NF-kB promoted these agents as lead
candidates for regulating the expression of adhesion molecules and
chemokines in glial cells.
Human 1321N1 astrocytoma were thus incubated with various
concentrations of the synthetic glucocorticoid, dexamethasone, for
15 h before stimulation with IL-1b (10 ng/ml) for a further 24 h.
Cell-surface expression of VCAM-1 and ICAM-1 was then quan-
titated, and supernatants removed from these cells were analyzed
for IL-8 content (Fig. 2). Dexamethasone caused concentration-
dependent inhibition of IL-1-induced VCAM-1 and ICAM-1 ex-
pression, inhibiting VCAM-1 expression more strongly than
ICAM-1. Similarly, the IL-1-induced expression of IL-8 was in-
hibited by dexamethasone in a concentration-dependent manner.
The effects of dexamethasone on IL-1 activation of NF-kB was
next examined to correlate the inhibitory effects on induction of
adhesion molecules and IL-8 with an action on NF-kB.
Dexamethasone fails to influence the IL-1b activation of NF-kB
in 1321N1 astrocytoma
1321N1 astrocytoma were incubated in the absence or presence of
various concentrations of dexamethasone for 15 h before stimula-
tion with IL-1b for a further 1-h period. Nuclear extracts were
prepared and assayed for NF-kB activity by EMSA (Fig. 3A). Be-
cause the objective was to correlate effects on NF-kB with effects
on NF-kB regulated genes, it was decided to use the specific
NF-kB motif from the IL-8 promoter. The motif from the IL-8
promoter was chosen in preference to that of either VCAM-1 or
ICAM-1 because the inhibitory effects on gene induction were
2114 EFFECTS OF GLUCOCORTICOIDS ON BRAIN CELLS
 at M
aynooth U









greatest with respect to IL-8. NF-kB-DNA complexes were unde-
tectable in extracts from unstimulated cells (Fig. 3A, lane 1). A
prominent protein-DNA complex was apparent in these extracts
but it represented a nonspecific protein-DNA interaction because
the formation of the complex was inhibited by the addition of an
unlabeled oligonucleotide containing either the wild-type or mu-
tated form of the NF-kB binding motif (Fig. 3B). The addition of
IL-1b to 1321N1 cells resulted in the formation of two additional
DNA-protein complexes of lower electrophoretic mobility (Fig.
3A, lane 7). These complexes represented the specific recognition
of the NF-kB-binding motif by proteins in the nuclear extracts
because their formation was inhibited by unlabeled oligonucleo-
tide, containing the wild-type NF-kB-binding motif but not by one
containing a mutated NF-kB site (Fig. 3B). The identity of the
NF-kB subunits in the complexes induced by IL-1 was investi-
gated by treating nuclear extracts from IL-1-stimulated cells with
antisera against p50, p65, or c-rel and observing any effects on
DNA-binding activity (Fig. 3C). Interestingly, the band of lowest
mobility appears as a doublet in these experiments, rather than a
singlet as in Fig. 3, A and B. This discrepancy may be due to the
extended running time applied for the subunit analysis, which may
facilitate superior resolution of complexes of similar sizes. The
IL-1-induced complexes were abolished by pretreating the extracts
with Abs against the p65 and p50 subunits of NF-kB but not by
anti-c-rel or an isotype control anti-human IgG. Although the com-
position of each complex cannot be definitively stated from these
studies, the analysis indicates that IL-1 activates forms of NF-kB
in 1321N1 cells that bind to the NF-kB-binding motif from the
IL-8 promoter as complexes containing p50 and p65.
FIGURE 1. Induction of adhesion molecules and chemokines by IL-1b
in 1321N1 astrocytoma. 1321N1 astrocytoma were treated for 24 h with
various concentrations of IL-1b. The cells were then measured for (A)
VCAM-1 and (B) ICAM-1 expression by direct ELISA, and supernatants
were examined for levels of (C) IL-8 by sandwich ELISA as described in
Materials and Methods. The levels of adhesion molecules are expressed in
terms of absorbance at 405 nm. The data represent mean 6 SEM of three
independent experiments.
FIGURE 2. Inhibition of IL-1b-induction of adhesion molecules and
IL-8 by dexamethasone in 1321N1 astrocytoma. 1321N1 astrocytoma were
pretreated for 15 h with various concentrations of dexamethasone and stim-
ulated for a further 24-h period with IL-1b (10 ng/ml). The cells were then
measured for (A) VCAM-1 and (B) ICAM-1 expression by direct ELISA,
and supernatants were examined for levels of (C) IL-8 by sandwich ELISA
as described in Materials and Methods. The results are expressed as per-
centages of values obtained in IL-1b-treated cells in the absence of dexa-
methasone. The data represent mean 6 SEM of three independent
experiments.
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Dexamethasone was assessed for its ability to inhibit such IL-1
activation of these NF-kB complexes. Three independent experi-
ments revealed that none of the wide-ranging concentrations of
dexamethasone displayed any reproducible effect on basal levels of
NF-kB or on the efficacy of IL-1 in activating NF-kB in 1321N1
cells (Fig. 3A). The inability of dexamethasone to block NF-kB
activation prompted a characterization of its influence on levels of
IkB in these cells. Indeed previous reports had suggested that ac-
tivation of NF-kB is sensitive to dexamethasone by virtue of the
latter’s ability to induce IkBa (16, 17). Western immunoblotting
analysis of cytosolic extracts from untreated and IL-1-stimulated
cells demonstrated that IL-1 effects proteolysis of IkBa in 1321N1
astrocytoma (Fig. 4), which is coincident with increased levels of
NF-kB in the nuclear extracts. However, dexamethasone failed to
induce IkBa in cells treated in the absence or presence of IL-1.
This lack of induction correlates with the failure of dexamethasone
to inhibit IL-1 activation of NF-kB. Thus, dexamethasone fails to
affect the nuclear translocation or DNA-binding activity of NF-kB
in 1321N1 astrocytoma.
Dexamethasone fails to affect the IL-1 induction of a NF-kB-
regulated reporter gene in 1321N1 astrocytoma
Previous studies had suggested that dexamethasone may exert in-
hibitory effects on NF-kB by modulating its transactivating ability
(20–23). To determine whether this was a potential mechanism by
which dexamethasone mediates its inhibitory effects on adhesion
molecule and IL-8 expression in 1321N1 cells, the influence of
dexamethasone on the ability of NF-kB to induce the expression of
a reporter construct was next examined. Human 1321N1 astrocy-
toma were transfected with a NF-kB-luciferase reporter construct
and incubated for 15 h with dexamethasone before stimulation in
the absence or presence of IL-1b for a further 24 h. Cell lysates
were prepared and assayed for luciferase activity (Fig. 5). Un-
treated cells demonstrated some basal expression of luciferase,
which was induced 17-fold with the addition of IL-1b. Pretreat-
ment of cells with various concentrations of dexamethasone failed
to affect basal or IL-1-induced levels of luciferase. Therefore, it
appears that dexamethasone has no effect on the transactivating
FIGURE 3. Effect of dexamethasone on
activation of NF-kB in 1321N1 astrocy-
toma. A, 1321N1 astrocytoma were pre-
treated for 15 h with various concentra-
tions of dexamethasone and stimulated for
a further 30 min in the absence (C) or pres-
ence (1IL-1) of IL-1b (10 ng/ml). Nuclear
extracts were prepared and assessed for
NF-kB activity as described in Materials
and Methods. B, Cultures of 1321N1 cells
were incubated in the absence (C) and
presence (IL-1) of IL-1b (10 ng/ml) for
1 h, after which nuclear extracts were pre-
pared and assessed for NF-kB activity in
the absence or presence of unlabeled oli-
gonucleotides (20 pmol) containing the
wild-type (WT) or mutated (MUT) NF-kB
motif from the IL-8 promoter. C, Extracts
were also examined for NF-kB binding ac-
tivity in the absence or presence of poly-
clonal antisera against the NF-kB subunits
p50, p65, and c-rel. Nonimmune IgG was
used a control. The arrows indicate the mo-
bility of protein-DNA complexes and un-
bound oligonucleotide (Free Probe). The
data are representative of three indepen-
dent experiments.
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ability of NF-kB in glial cells. These results propose that glucocor-
ticoids can produce well-defined antiinflammatory responses in
1321N1 astrocytoma by inhibiting the induction of adhesion mol-
ecules and IL-8 yet by a mechanism independent of NF-kB.
Dexamethasone fails to affect IL-1 activation of NF-kB but
inhibits IL-1 induction of VCAM-1, ICAM-1, and IL-8 in
SK.N.SH neuroblastoma
To ensure that the above effects are not simply artifacts of the
1321N1 astrocytoma cell line, the effects of dexamethasone on
SK.N.SH neuroblastoma, another cell of neural origin, was next
examined. The ability of dexamethasone to affect IL-1 activation
of NF-kB in these cells was first examined. SK.N.SH cells were
pretreated with various concentrations of dexamethasone for 15 h
before stimulation for an additional 1 h with or without IL-1. Nu-
clear extracts from these cells were analyzed for NF-kB by EMSA
(Fig. 6). SK.N.SH cells contained basal levels of a NF-kB-DNA
complex, and the IL-1 caused an increase in the quantity of this
complex. Dexamethasone failed to affect the basal or IL-1-stimu-
lated levels of the complex, indicating that it has no influence on
the ability of IL-1 to induce nuclear translocation and DNA bind-
ing activity of NF-kB. Experiments were then performed to assess
if dexamethasone could produce antiinflammatory effects in
SK.N.SH cells despite its inability to affect NF-kB. IL-1 was ini-
tially shown to strongly induce the expression of VCAM-1,
ICAM-1, and IL-8 in SK.N.SH cells (data not shown). The inhib-
itory effects of dexamethasone on the IL-1 induction of the adhe-
sion molecules and IL-8 was then assessed (Fig. 7). Dexametha-
sone caused a dose-dependent inhibition of the IL-1-induced
expression of VCAM-1 and ICAM-1 (Fig. 7, A and B) with the
expression of both adhesion molecules being reduced by compa-
rable degrees. Similarly the IL-1-induced expression of IL-8 was
also inhibited in a dose-dependent fashion by dexamethasone in
these cells (Fig. 7C). These studies, in conjunction with the
equivalent ones in 1321N1 astrocytoma, emphasize that the an-
tiinflammatory effects of dexamethasone are not always depen-
dent on inhibition of NF-kB.
Discussion
Many recent reports have indicated NF-kB as being an important
target for mediating the antiinflammatory effects of glucocorticoids
(16, 17). This promoted glucocorticoids as being efficacious drugs
in controlling the expression of NF-kB-responsive genes. The lat-
ter include the genes encoding leukocytic adhesion molecules such
as VCAM-1 (24) and ICAM-1 (25) and chemokines such as IL-8
(26). Indeed, it has been shown that the NF-kB-binding site in the
promoter regions of these genes is the crucial cis-element in con-
ferring IL-1 responsiveness on adhesion molecule (27) and IL-8
(28) expression. The present study was thus initiated to character-
ize the potential inhibitory effects of glucocorticoids on the IL-1-
induction of these proinflammatory molecules in cells of neural
origin. This is of major clinical relevance because the inappropri-
ate expression of adhesion molecules and chemokines in brain
cells can lead to the generation of neuropathological conditions.
The initial experiments demonstrated that the synthetic glucocor-
ticoid dexamethasone could produce the predicted inhibitory ef-
fects on the IL-1 induction of VCAM-1, ICAM-1, and IL-8 in
FIGURE 4. Effect of dexamethasone on levels of IkBa protein in
1321N1 astrocytoma. 1321N1 astrocytoma were pretreated for 15 h with
various concentrations of dexamethasone and stimulated for a further 30
min in the absence (Control) or presence (1IL-1) of IL-1b (10 ng/ml).
Cytosolic extracts were prepared and analyzed by Western immunoblotting
for levels of IkBa using anti-IkBa (Mad 3) (C-15) from Santa Cruz Bio-
technology. The data are representative of three independent experiments.
FIGURE 5. Failure of dexamethasone to repress induction of a NF-kB-
regulated reporter gene in 1321N1 astrocytoma. 1321N1 astrocytoma, pre-
viously transfected with a plasmid containing a NF-kB-regulated luciferase
gene, were pretreated for 15 h with various concentrations of dexametha-
sone and stimulated for a further 24 h in the absence (Control) or presence
(1IL-1) of IL-1b (10 ng/ml). Cell extracts were measured for luciferase
activity, and the results are expressed as light units normalized for protein.
The data represent mean 6 SEM of three independent experiments.
FIGURE 6. Effect of dexamethasone on activation of NF-kB in
SK.N.SH neuroblastoma. SK.N.SH neuroblastoma were pretreated for 15 h
with various concentrations of dexamethasone and stimulated for a further
30 min in the absence (C) or presence (1IL-1) of IL-1b (10 ng/ml). Nu-
clear extracts were prepared and assessed for NF-kB activity as described
in Materials and Methods. The arrow indicates the mobility of the NF-
kB-DNA complex. The data are representative of three independent
experiments.
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1321N1 astrocytoma. The expression of IL-8 was inhibited to the
greatest extent, suggesting that the glucocorticoid-sensitive path-
way plays a major role in the induction of IL-8. However, the
range of concentrations of dexamethasone that inhibited the ex-
pression of the proinflammatory molecules were completely inef-
fectual in affecting the activation of NF-kB. Dexamethasone failed
to block IL-1 from stimulating the nuclear translocation and DNA-
binding activity of NF-kB as determined by EMSA analysis. The
NF-kB-DNA complexes that were induced by IL-1 contained both
p50 and p65 based on the ability of Abs against these two subunits
to block formation of the complexes. The inability of dexameth-
asone to block translocation of these subunits into the nucleus is in
apparent contrast to previous studies (16, 17) that have shown that
dexamethasone may reduce the amount of translocated nuclear p65
in response to proinflammatory cytokines such as TNF. This dis-
crepancy may be explained by the proposal that up-regulation of
IkBa in response to steroids, which was the suggested model by
which translocation of p65 was decreased, may not be a universal
mechanism. Indeed, a recent report (29) has shown that the levels
of IkB in the neuronal cortex and hippocampus are lower in dex-
amethasone-treated rats than in untreated animals. In contrast, pe-
ripheral cells from the same animals show elevated IkB levels
following treatment with dexamethasone. The present study,
where dexamethasone fails to affect levels of IkB, confirms further
that induction of IkBa protein by glucocorticoids, and the conse-
quential reduction in nuclear levels of active NF-kB is not a uni-
versal phenomenon and is cell-type specific.
The inability of dexamethasone to affect the IL-1-induced nu-
clear translocation or DNA-binding activity of NF-kB did not pre-
clude the possibility that it may produce its antiinflammatory ef-
fects in 1321N1 cells by reducing the transactivation potential of
NF-kB. Indeed, previous reports had proposed that glucocorticoids
elicit their immunosuppressive effects by mediating direct protein-
protein interactions between members of the steroid-receptor fam-
ily and the DNA-binding subunits of NF-kB. Several studies have
reported such interactions in vitro, which were found to suppress
NF-kB transcriptional activity (20–23). De Bosscher et al. (23)
showed that these direct protein interactions may interfere with the
transactivation potential of NF-kB. They observed that gene ex-
pression driven by a chimeric protein containing the transactivat-
ing p65 subunit of NF-kB linked to the DNA-binding domain of
the yeast GAL4 protein was strongly suppressed by glucocorti-
coids. Because the DNA-binding activity of the GAL4 fusion pro-
tein was not affected, it was concluded that the glucocorticoids
must therefore interfere with the transactivating potential of the
NF-kB p65 subunit. Further support for this model emerged when
deletion analysis revealed an absolute requirement for the C-ter-
minal transactivation domain of p65 in repression of transcrip-
tional activity by glucocorticoids (30). Because the present studies
had shown that IL-1 could induce the formation of NF-kB-DNA
complexes containing p65 (Fig. 3C), it was decided to assess the
ability of dexamethasone to affect the ability of IL-1 to induce the
expression of a NF-kB-regulated reporter gene, luciferase, which
had previously been transfected into 1321N1 cells. While IL-1
effected an impressive 17-fold induction of the reporter gene,
dexamethasone failed to affect this induction. This again suggests
that the antiinflammatory effects of dexamethasone in 1321N1
cells are mediated by a mechanism(s) independent of NF-kB.
To ensure that the observed effects are not simply artifacts of the
1321N1 cell system similar studies to the above were performed
on SK.N.SH neuroblastoma, another widely used model cell sys-
tem of neural origin. The effects that were observed in 1321N1
cells were mirrored in the SK.N.SH cells. Dexamethasone caused
a dose-dependent inhibition of the IL-1 induction of the adhesion
molecules VCAM-1 and ICAM-1 and the chemokine IL-8, but the
same range of concentrations failed to affect activation of NF-kB.
This suggests that the scenario whereby glucocorticoids may pro-
duce immunosuppressive and antiinflammatory effects in cells and
NF-kB need not be involved in mediating the effects may be wide-
spread and is not limited to a single cell type. Thus the mecha-
nism(s) by which glucocorticoids are immunosuppressive and an-
tiinflammatory are likely to be multifactorial. Some reports have
shown glucocorticoids to down-regulate NF-kB activity by induc-
ing IkBa protein (16, 17), whereas other studies have also de-
scribed an inhibition of NF-kB but by a process independent of
IkB (20, 31). In contrast, another recent report has demonstrated
that glucocorticoids can also potentiate activation of NF-kB in
some cell types (32).The present study adds further to the com-
plexity and debate relating to the mechanism of glucocorticoid
action in that glucocorticoids fail to affect in any way the NF-kB
system in astrocytoma or neuroblastoma cells, yet retain their abil-
ity to produce effects that are antiinflammatory in nature.
FIGURE 7. Inhibition of IL-1b-induction of adhesion molecules and
IL-8 by dexamethasone in SK.N.SH neuroblastoma. SK.N.SH neuroblas-
toma were pretreated for 15 h with various concentrations of dexametha-
sone and stimulated for a further 24-h period with IL-1b (10 ng/ml). The
cells were then measured for (A) VCAM-1 and (B) ICAM-1 expression by
direct ELISA, and supernatants were examined for levels of (C) IL-8 by
sandwich ELISA as described in Materials and Methods. The results are
expressed as percentages of values obtained in IL-1b-treated cells in the
absence of dexamethasone. The data represent mean 6 SEM of three in-
dependent experiments.
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